Interpace Biosciences Total Liabilities

The latest total liabilities for IDXG is $11M as of June 2026. That compares with $14M in the prior-year period — down 16.6% year over year. Investors often review this figure alongside Interpace Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, IDXG's total liabilities moved from $14M to $11M — a 16.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Interpace Biosciences's operating scale or balance-sheet position.

A total liabilities figure of $11M for IDXG is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting IDXG's total liabilities ($11M), review year-over-year change from $14M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.